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• Background: Purinergic signalling is involved in several physiological and pathophysiological processes. P2X7 receptor (P2X7R) is a 
calcium-permeable ion channel that is gaining interest as a potential therapeutic target for the treatment of different diseases including 
inflammation, pain, psychiatric disorders and cancer. P2X7R is ubiquitously expressed and sensitive to high ATP levels, usually found in tumor 
microenvironment. P2X7R regulates several cell functions, from migration to cell death, but its selective contribution to tumor progression 
remains controversial.  
• Objective: We review the most recent patents focused on the use of P2X7R in the treatment of cancer.  
• Results and Conclusion: P2X7R is an intriguing purinergic receptor that plays different roles in tumor progression. Powerful strategies able 
to selectively interfere with its expression and function should reveal helpful in the development of new anti-cancer therapies.  
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1. INTRODUCTION 
Purinergic signalling involves purine nucleotides and 
nucleosides such as adenosine 5’-triphosphate (ATP) and 
adenosine (ADO) [1]. It is involved in short-term 
neurotransmission, neuromodulation and secretion) and long-
term processes (proliferation, differentiation, migration and 
death in development and regeneration) acting on a variety of 
fferent cell types [2]. 
The effects on target cells depend on the binding with 
purinergic receptors which are classified in two major 
families: the metabotropic P1 receptors for ADO and the P2 
family, including P2Y metabotropic and P2X ionotropic sub-
classes [3, 4].  
P2Y (P2YR) comprise eight subtypes of G protein-coupled 
receptors (GPCR) activated by adenine and uridine 
nucleotides (ATP, ADP, UTP and UDP): some of them couple 
mainly with Gq, activating PLCb, while others associate 
preferentially with pertussis toxin-sensitive Gi/o, suppressing 
adenylyl cyclase activity [5] .  
P2X receptors (P2XR) are ATP-gated calcium-permeable 
cation channels. Seven subunits (P2X1-7) assemble into 
homo- or heterotrimeric functional channels, activated upon 
the binding with three molecules of ATP [6]. Among them, 
P2X7 receptor (P2X7R) is gaining growing interest as a 
potential therapeutic target for the treatment of numerous 
diseases, including cancer [6, 7].  
2. P2X7 RECEPTOR  
 P2X7 receptor (P2X7R) is unique among all the other P2X 
isoforms. It differs structurally in the long intracellular 
carboxy-terminal tail [8], pharmacologically in its low affinity 
towards ATP (EC50 >100µM) [9], but especially for its role as 
a trigger of inflammatory cytokine release through the large 
conductance pore, facilitating ions and molecules efflux [10, 
11]. Brief recruitment of the channel, when ATP binds the 
receptor in a range of milliseconds, has long been known to 
trigger the small cation-selective pore opening. On the other 
hand, prolonged ATP exposure in a range of seconds results 
in a larger pore formation, allowing molecules up to 900 Da 
to flow, and eventually leading to cell death by apoptosis or 
autophagy [6, 12]. Nowadays, the molecular mechanisms 
responsible of the large molecules efflux through P2X7R are 
still not fully elucidated [13, 14]. 
Functional P2X7R is a trimer and its three-dimensional 
monomer structure could be compared to the shape of a 
dolphin [15]. The ATP binding site is located at the interface 
of each pair of monomers, giving rise to the requirement of 
three molecules of ATP for channel opening. The recent 
availability of chicken and mammalian P2X7R crystal 
structures shows that the most largely used antagonists may 
bind a unique allosteric site, thus allowing the design of 
improved antagonists by modelling binding sites of the known 
and presumed inhibitors [13].  
Human P2X7R has ten splice variants (P2X7A-J), is highly 
polymorphic and more than 150 non-synonymous SNPs have 
been studied [8]. These variants are gaining huge interest in 
relation to human health and disease [16, 17], as demonstrated 
by the development and publication of many patents. At least 
eight loss-of-function SNPs have been identified, while for 
splice variants the scenario is more complex. Among all the 
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isoforms, P2X7B shares the similar predominant distribution 
of the canonical full-length P2X7A, even if the receptor made 
by P2X7B monomer assembly lacks the macropore function 
but maintains channel activity and stimulates growth [8]. All 
the isoforms originate from alternative splicing which affects 
their channel functionality: some non-functional P2X7R 
(nfP2X7R) are reported in literature and are associated with 
cancer [18, 19]. Different isoforms may assembly in order to 
form heterotrimers with impaired signalling [19, 20]. A patent 
from Barden and Gidley-Baird [21] provides antibodies that 
specifically distinguish between functional and non-
functional P2X7R, by targeting the characteristic amino acid 
sequence (200-216) called E200 [19, 22].  
Many studies point to a critical role of P2X7R-dependent 
signalling in a number of physiological and pathological 
processes, including inflammation, pain, psychiatric 
disorders, and cancer. Growing evidences highlighted the 
pivotal role of P2X7R in cancer progression. Consistently, its 
functionality is strictly dependent on two hallmarks of tumoral 
microenvironment [23]: acidosis and low O2 [24]. High 
extracellular proton levels act allosterically on the 
extracellular histidine 130  (H130) [25]. Conflicting data 
suggest that hypoxic conditions may modulate P2X7R 
expression level [26, 27].  
 
3. P2X7 RECEPTOR AND INFLAMMATION 
 P2X7R is upregulated on immune cells (neutrophils, 
monocytes, eosinophils, mast cells, macrophages and 
lymphocytes) during inflammation [10] and can be considered 
as an immunomodulatory receptor. ATP released from injured 
cells acts as a “danger signal” by signalling to upregulated 
P2X7R and increasing immune responses which involve the 
release of inflammatory cytokines through the larger pore of 
the channel [10, 28]. Since a wide range of diseases is 
associated with P2X7R-mediated inflammation, there has 
been a growing interest in patent small antagonists of P2X7R 
as a strategy to counteract various pathological conditions 
related to inflammation, including cancer [29]. A patent from 
Hilpert and colleagues [30] discussed the preparation and use 
of P2X7R antagonists for pharmaceutical use. Many other 
patents have been developed since 1999 when Astra Zeneca 
firstly reported the possible therapeutic application of P2X7R 
inhibitors to treat inflammation and other diseases [31]. 
Interestingly, the role of P2X7R antagonists in rheumatoid 
arthritis (RA) is controversial. Three compounds have been 
tested in clinical trials: Evotec’s EVT-401, AstraZeneca’s 
AZD-9056 and Pfizer’s CE-224535. The last two didn’t show 
any significant efficacy in RA treatment and for this reason 
P2X7R doesn’t appear to be a functional target in RA [9]. 
Despite the clinical failure of these two compounds in phase 
II, P2X7R antagonists are still promising and other human 
clinical trials have been launched in order to investigate their 
therapeutic potential in Crohn’s and chronic obstructive 
pulmonary diseases [6]. Importantly, high levels of P2X7R 
have been found in neuronal degeneration (e.g. Alzheimer’s 
disease [32]), neuropatic pain [33] and in some cancers. A 
method for preventing and/or treating inflammatory diseases 
and other disorders associated with P2X7 upregulation 
involves the use of RNAi technology [34]. 
Tumor microenvironment includes different immune cells, 
including monocytes, macrophages, dendritic cells, 
lymphocytes and myeloid-derived suppressor cells, that 
enable tumor growth and progression by directly interacting 
with cancer cells. This highly inflammatory milieu modulates 
the immune response against tumors and the signalling 
through P2X7R on dendritic cells is crucial for the activation 
of NLRP3 inflammasome [35], which is the most versatile and 
clinically implicated inflammasome [36]. The subsequent 
release of IL-1β leads to the stimulation of CD4+ and CD8+ 
lymphocytes T which mediate the anti-tumor responses. A 
recent patent discussed a method for treating cancer by 
polymyxin B administration in combination with ATP as a 
novel tool to target T regulating (Treg) CD4+ CD25+ 
lymphocytes, preventing excessive immune reactions and are 
known as T cells suppressors [37]. In particular, the role of 
ATP in this patent is to stimulate P2X7R on Treg in order to 
promote apoptosis. 
 
4. P2X7 RECEPTOR AND CANCER 
 As mentioned above, there is a tight connection between 
P2X7R and cancer, as suggested by multiple lines of evidence. 
Firstly, inflammatory pathways concur to the pathogenesis of 
oncogenic disorders. Moreover, the tumor microenvironment 
is characterized by accumulation of ATP up to the millimolar 
range, which can be directly released by cancer cells, 
promoting their migration and metastatisation [6], or 
indirectly through cell death caused by as hypoxia, 
inflammation, mechanical stress and non-targeted therapies 
[19].  
Tumor microenvironment is composed of cancer and stromal 
cells, such as cancer-associated fibroblasts, immune and 
endothelial cells, even if its composition may change 
depending on tumor type [38].  The interaction between 
cancer cells and the surrounding medium is crucial in 
determining the fate of the tumor, its ability to growth and 
metastasize [39], especially linked to the effectiveness of host 
anti-tumor immune response [38].  
In order to support tumor growth and its invasive and 
metastatic potential, cancer cells promote tumor 
neovascularization supported by endothelial and endothelial 
progenitor cells (respectively EC and EPC). Interesting, 
several Ca2+-permeable ion channels play a role in the 
sustainment of tumor-neoangiogenesis and P2X7R is among 
them [40–42]. Consistently, in vitro experimental evidences 
show the modulation of the main molecular players involved 
in Ca2+ signalling in both tumor endothelial cells (TEC) and 
tumor endothelial progenitor cells (TEPC) [40, 43–48]. Even 
though Ca2+ machinery is far from being used as a target for 
the anti-cancer therapies [40, 49], the remodelling of 
Ca2+signals in TEC could contribute to the resistance of some 
tumors to standard anti-angiogenic treatments, such as anti-
VEGF therapies [43, 50, 51]. Another possible explanation for 
the resistance to anti-VEGF therapy is the ability of EPCs to 
reach tumor microenvironment and concur to 
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neovascularization [52, 53]. This recruitment is called 
“homing” and it is induced by several chemokines, among 
which SDF-1α plays a pivotal role [54]. It has been shown that 
the activation of P2X7R on EPCs promotes their homing to 
gliomas in vivo, thus highlighting a possible therapeutic 
strategy to overcome the their anti-angiogenic resistance [52]. 
Other pro-angiogenic roles for P2X7R are reported in 
literature: its activation on cancer cells was associated with 
increased HIF-1α activity  [55], vascular endothelial growth 
factor (VEGF) [56, 57] and matrix metalloproteinases (MMP) 
production, such as MMP-2 and MMP-9 [58], therefore 
promoting not only tumor growth and angiogenesis [59] but 
also invasiveness and metastasis spreading [35, 58, 60]. For 
these reasons P2X7R blockers could be considered as anti-
angiogenic molecules and is not surprising that growth and 
neoangiogenesis of P2X7R-expressing tumors are inhibited 
not only by Avastin, an anti-VEGF antibody, but also by 
pharmacological P2X7R blockade and P2X7R silencing in 
vivo [56]. 
P2X7R is over-expressed in cancer cells from many malignant 
human tumors including leukaemia [61], neuroblastoma [57, 
62], mesothelioma [63], esophageal squamous cell carcinoma 
[64], pancreatic ductal adenocarcinoma [65], breast [66] and 
skin [67] cancer. This is not surprising, considering its 
capability to enhance survival and growth in the absence of 
serum [68], and make it a good tumoral biomarker. In 
addition, a patent is based on the use of a P2X7R splicing 
variant as a biomarker for rhabdomyosarcoma, the most 
frequent soft tissue sarcoma in childhood [69]. Although the 
involvement of P2X7R in cancer is well established, its actual 
role is still debated. Intriguingly, P2X7R activation on cancer 
cells  exerts opposite effects, being pro-tumoral is some 
conditions and anti-tumoral in others [35]. Basal activation of  
P2X7R contributes to tumor progression by increasing 
oxidative phosphorylation and aerobic glycolysis, and leading 
to the increase of intracellular ATP content [55]. In this 
scenario, tumor cells gain a proliferative advantage through 
the activation of several intracellular pathways such as 
NFACTc1, ERK, PI3K/Akt and HIF-1α [70]. Consistently, 
many pharmaceutical drugs that act as P2X7R blockers have 
been used in pre-clinical animal models: they include oATP 
for colon cancer [56], BBG for ovarian cancer [71], 
AZ10606120 for pancreatic ductal adenocarcinoma [65] and 
A740003 for neuroblastoma [57].  There is a growing interest 
in developing new compounds or antibodies with similar 
effects. For instance Barden and Gigley-Baird presented a 
novel method for detection and treatment of cancer by the use 
of antibodies that bind P2X7R [72, 73]. In particular, these 
findings relate to a novel epitope on nfP2X7R that has been 
used for the generation of the antibodies [74]. The expression 
of nfP2X7R in cancer cells is more associated to a pro-tumoral 
effect than canonical P2X7R, due to its inability to form 
functional pores and to induce cell death [19]. Other 
promising patents focused on nfP2X7R have been published, 
some of which aimed to the production of antibodies to form 
an immune complex with nfP2X7R: this strategy may provide 
a method for determining whether a cell, a tissue or extra 
cellular fluid includes nfP2X7R [21, 75]. Despite the 
promising results in the aforementioned pre-clinical models, 
novel therapies based on P2X7R-targeted strategy are feasible 
only when the receptor is overexpressed. Tumors with low 
P2X7R expression levels seem only slightly responsive [35].  
As mentioned above, not only pro-tumoral effects are 
associated to P2X7R. Recent in vitro evidences pointed out a 
possible anti-angiogenic role of P2X7R on TEC [76]. The 
anti-cancer effect of P2X7R could be hampered in vivo by the 
conditions usually found in some solid tumors, as acidosis and 
hypoxia, which counteract P2X7R functionality. Moreover, 
the high ATP levels, which are typically found in tumor 
stroma, overstimulate P2X7R in order to induce tumor cell 
death by inducing pro-apoptotic pores. This was demonstrated 
in many types of cancer but although the outcomes are 
exciting, clinical trials failed to confirm any anti-cancer effect 
for extracellular ATP stimulation. A possible explanation 
could be the expression of nfP2X7R together with the onset 
of a resistance towards high ATP concentrations [35]. 
Through these mechanisms, cancer cells may become able to 
fulfil P2X7R-dependent functional responses but avoiding 
lethal consequences [77]. Moreover, a recent study carried out 
by Young et al suggests a further mechanism to evade ATP-
induced cytotoxicity, which involves MMP-2-dependent 
cleavage of P2X7R [78]. Despite further investigation is 
needed, strategies aimed at enhancing the potential P2X7R-
dependent anti-cancer effect of ATP could be an alternative 
approach to avoid cancer cell death escape [35]. Consistently, 
a patent from Gorodeski and Fu provides a method for 
inducing apoptosis in premalignant and cancerous cells by 
administering BzATP, a P2X7 agonist [79]. In particular, this 
method targets a specific mechanism of apoptosis in cancer 
cells, which does not involve inflammatory changes, 
abnormal skin or systemic effects in models of skin 
carcinogenesis. BzATP reduced papilloma skin formation and 
triggered the involution of already developed papillomas. 
Another interesting patent develops a method for the 
treatment of primary cancer and bone metastasis, based on 
P2R agonists and P1R antagonists [80]. In the field of 
oncogenic neurological disorders, many studies reported the 
involvement of calcium channels in malignant brain tumor 
progression [81–84]. Importantly, P2X7R regulates 
proliferation and migration of human glioma cancer cells, and 
its expression increases with the grade of the tumor [60]. Since 
2008, several pharmaceutical companies have patented many 
CNS available compounds. The principal issue in CNS 
disorders is to identify molecules able to permeate the blood-
brain barrier (BBB) [85]. For instance, Glaxo Smith Kline’s 
GSK-1482160 is a potent BBB penetrant P2X7R antagonist, 
which completed phase I clinical trial in human volunteers and 
was shown to have a role in reducing inflammatory pain. 
Thanks to its ability to target P2X7R and to be radiolabelled 
with 11C, GSK-1482160 could be useful as a biomarker for 
neuroinflammation via PET [86]. Inflammatory pathways, 
activated by increased levels of extracellular adenine 
nucleotides in the microenvironment and the subsequent 
purinergic receptors activation, are involved in a number of 
neuro pathological conditions [87, 88] such as 
neurodegenerative, neuropsychiatric, neuropathic pain and 
cancer [89]. Neuroinflammation is the major component in 
neurodegenerative disease [90] and purinergic receptors could 
2   Journal Name 2017, Vol. 0, No. 0 Principal Author Last Name  et al. 
 
be valuable targets in the treatment of these pathologies. 
Particularly, P2X7R antagonists are promising agents for the 
treatment [28] of Alzheimer’s Disease [32], Parkinson’s 
Disease [91], multiple sclerosis [92], amyotrophic lateral 
sclerosis [93] and also epilepsy [94]. Many molecules have 
been patented for the treatment of these neurodegenerative 
diseases [95–98]. Even if these approaches are not directly 
designed for cancer treatment, they could be helpful to 
counteract neuroinflammation associated with oncogenic 
neurological disorders. Interestingly, many P2X7R 
modulators have been patented as methods to treat affective 
and mood disorders for the treatment of depression, bipolar 
disorder, anxiety and sleep disorders [95, 97, 99, 100] and, 
nonetheless, some of them refer also at their possible 
application in the treatment of cancer [95, 97]. 
CONCLUSION 
 P2X7R is a purinergic receptor involved in inflammation 
and cancer progression. Its activation can produce both pro- 
and anti-tumoral effects, depending on the cell type as well as 
on a variety of different factors. It is considered a key 
mediator of anti-tumoral immune response [101], but its 
expression on cancer cell membranes seems to mediate a dual 
role  (Fig. 1). In some conditions, P2X7R triggers 
programmed cell death [102]: however, at least three factors 
contribute to counteract this activity: the preferential 
expression of a nfP2X7R [19], its cleavage by MMP-2 [78] 
and the influence of tumor microenvironment [77]. On the 
other hand, P2X7R is known to be a pro-tumor protein 
promoting tumor growth, angiogenesis, invasiveness and 
metastasis spreading [55, 56, 58]. In the present work we 
reviewed some of the most recent patents (Table 1) that 
involve P2X7R use in the treatment of cancer. Due to the 
aforementioned opposite biological effects associated to this 
intriguing purinergic receptor, some patents provide methods 
based on its recruitment, while other are focused on the 
development and use of antagonists and/or antibodies aimed 
to interfere with its activity. 
 
CURRENT & FUTURE DEVELOPMENTS  
Future efforts should be devoted to overcome the current 
conflicting mechanistic models proposed for a role of P2X7R 
in tumor progression: a helpful contribution will hopefully be 
provided by the development of new and powerful drugs or 
molecular strategies to selectively interfere with the large 
number of P2X7R splicing variants and polymorphisms.  
Another interesting issue would be to design novel therapies 
focused on the use of non-functional forms of P2X7R as 
preferential oncological targets, especially because strong 
evidence suggests its high expression in different cancer cells 
and its absence in healthy tissues. In particular, the clear 
definition of the differential biological roles for ‘canonical’ 
ion channel ability and pro-apoptotic pore formation will 
shed light on the still elusive dual nature of P2X7R [18, 19]. 
Figure 1.  Schematic representation of P2X7R dual-role in cancer cells: pro- and anti-tumor effects are shown. Its activation can enhance 
tumor growth by promoting proliferation, angiogenesis, invasiveness and metastasis. On the contrary, it could lead to cancer cell death, 
reducing tumor growth, through macropore formation. This is counteracted by three main factors: nfP2X7R preferential expression, the 
cleavage of P2X7R by MMP-2 and by the possible onset of a resistance towards high ATP levels. 
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Title and Authors 
 
 
Publication Number  
 
P2X7R Involvment 
New tumor marker for the 
rhabdomyosarcoma 
 
(Gesche et al, 2018)  
US20180256743 
 
P2X7R splicing variant is 
expressed on RMS cell surface 
Methods and Compositions to 
Inhibit P2x7 Receptor Expression 
 
(Jimenez et al, 2011) 
EP2287301 
 
RNAi technology to 
downregulate P2X7R expression 
on cancer cells 
In vitro method for modifying the 
depletion profile of treg cells present 
in a total splenocyte population of a 
biological sample by means of the 
isolation, culturing and exposure 
thereof to an atp and polymixin b 
medium 
 
(Acuna et al, 2014) 
US20140371159 
 
Activation of P2X7R on Treg 
cells enhances anti-tumor 
responses 
Novel p2x7 epitopes 
 
(Gidley-Baird & Barden, 2018) 
US15910987 
 
Treatment of cancer by antibodies 
anti-P2X7R 
Anti- p2x7 peptides and epitopes 
 
(Barden & Gidley-Baird, 2016) 
EP2318438B1 
 
Identification of novel epitope on 
cancer-related nfP2X7R 
Combination therapy 
 
(Barden & Gidley-Baird, 2018) 
EP2726095B1 
 
Humoral response against P2X7R 
in individuals having cancer 
P2X7 inhibition of epithelial 
cancers and papillomas 
 
(Gorodeski & Fu, 2013) 
EP2509605 
 
Local activation of PX7R inhibits 
development and progresion of 
epidermal premalignant lesions 
Methods for treatment of primary 
cancer and cancer metastasis 
 
(Jiang & Zhou, 2015) 
US20150297623 
 
P2X7R agonists as a method for 
the treatment of metastatic cancer 
Table 1. Patents Regarding P2X7R in the Treatment of Cancer 
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